See All News - tctmd.com

News

News Industry News

Arterial Remodeling Technologies (‘ART’) reports 30-day results for the ‘ARTDIVA’ clinical trial of its next-generation bioresorbable stent at ‘TCT 2013’ annual scientific meeting

October 28, 2013

News Conference News TCT 2013

Cre8, BioFreedom Polymer-Free DES Show Promise

October 28, 2013

News Conference News TCT 2013

Preliminary Data Show Potential of Renal Denervation in Several Settings

October 28, 2013

News Industry News

Anti-Clotting Agent Helps Reduce the Risk of Intraprocedural Events during Percutaneous Coronary Intervention

October 28, 2013

News Conference News TCT 2013

At a Transradial PCI Center, Transfemoral Patients Undergo More Complex Procedures, Have Poorer Outcomes

October 28, 2013

News Industry News

Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure

October 28, 2013

News Conference News TCT 2013

Bioresorbable Scaffold Stands Ground Next to Current DES

October 28, 2013

News Industry News

NEW DATA CONTINUE TO SHOW SIGNIFICANT AND SUSTAINED BLOOD PRESSURE REDUCTION WITH BOSTON SCIENTIFIC VESSIX™ RENAL DENERVATION SYSTEM

October 28, 2013

News Industry News

META-ANALYSIS DEMONSTRATES REDUCTION IN MORTALITY WITH PCI COMPARED TO MEDICAL THERAPY IN STABLE PATIENTS SELECTED ON THE BASIS OF ISCHEMIA

October 28, 2013

News Conference News TCT 2013

ABSORB III and IV Trials Aim to Prove Superiority of BVS

October 28, 2013

Advertisement

News

Arterial Remodeling Technologies (‘ART’) reports 30-day results for the ‘ARTDIVA’ clinical trial of its next-generation bioresorbable stent at ‘TCT 2013’ annual scientific meeting

Cre8, BioFreedom Polymer-Free DES Show Promise

Preliminary Data Show Potential of Renal Denervation in Several Settings

Anti-Clotting Agent Helps Reduce the Risk of Intraprocedural Events during Percutaneous Coronary Intervention

At a Transradial PCI Center, Transfemoral Patients Undergo More Complex Procedures, Have Poorer Outcomes

Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure

Bioresorbable Scaffold Stands Ground Next to Current DES

NEW DATA CONTINUE TO SHOW SIGNIFICANT AND SUSTAINED BLOOD PRESSURE REDUCTION WITH BOSTON SCIENTIFIC VESSIX™ RENAL DENERVATION SYSTEM

META-ANALYSIS DEMONSTRATES REDUCTION IN MORTALITY WITH PCI COMPARED TO MEDICAL THERAPY IN STABLE PATIENTS SELECTED ON THE BASIS OF ISCHEMIA

ABSORB III and IV Trials Aim to Prove Superiority of BVS

Search News

Advertisement

Advertisement

News

Search News

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content